

Neueste Fortschritte in der Behandlung des Multiplen Myeloms – ein Update vom ASCO und EHA 2023 (S. 8–10)

C. Michel, M.-S. Raab

Literatur:

1. Cowan AJ et al. Diagnosis and Management of Multiple Myeloma: A Review. JAMA 2022; 327(5): 464–77
2. Knop S et al. Carfilzomib, lenalidomide, and dexamethasone (KRd) versus elotuzumab and KRd in transplant-eligible patients with newly diagnosed multiple myeloma: Post-induction response and MRD results from an open-label randomized phase 3 study. J Clin Oncol 2023; 41(16_suppl): 8000
3. Dhakal B et al. First phase 3 results from CARTITUDE-4: Cilta-cel versus standard of care (PVd or DPd) in lenalidomide-refractory multiple myeloma. J Clin Oncol 2023; 41(17_suppl): LBA1064. Sperling AS et al. Updated phase I study results of PHE885, a T-charge manufactured BCMA-directed CAR-T cell therapy, for patients (pts) with r/r multiple myeloma (RRMM). J Clin Oncol 2023; 41(16_suppl): 8004
5. Mohty M et al. Elranatamab, a B-cell maturation antigen (BCMA)-CD3 bispecific antibody, for patients (pts) with relapsed/refractory multiple myeloma (RRMM): Extended follow up and biweekly administration from the MagnetisMM-3 study. J Clin Oncol 2023; 41(16_suppl): 8039
6. Cohen YC et al. First results from the RedirecTT-1 study with teclistamab (tec) + talquetamab (tal) simultaneously targeting BCMA and GPRC5D in patients (pts) with relapsed/refractory multiple myeloma (RRMM). J Clin Oncol 2023; 41(16_suppl): 8002
7. San-Miguel J et al. Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma. N Engl J Med 2023; 389: 335–47

Update zu Kopf-Hals-Malignomen vom ASCO 2023 (S. 12–15)

C. Reichel

Literatur:

1. Rosenberg A et al. Neoadjuvant nivolumab, paclitaxel, and carboplatin followed by response-stratified chemoradiation in locoregionally advanced HPV negative head and neck squamous cell carcinoma (HNSCC): The DEPEND trial. J Clin Oncol 41, 2023 (suppl 16; abstr 6007)
2. Wong W et al. Neoadjuvant cemiplimab with platinum-doublet chemotherapy and cetuximab to de-escalate surgery and omit adjuvant radiation in locoregionally advanced head & neck squamous cell carcinoma (HNSCC). J Clin Oncol 41, 2023 (suppl 16; abstr 6019)

3. Bai C et al. Induction therapy of toripalimab combined with docetaxel and cisplatin in locally advanced hypopharyngeal squamous cell carcinoma (HPSCC): A single-arm, phase II clinical trial. *J Clin Oncol* 41, 2023 (suppl 16; abstr 6070)
4. Ou X et al. Induction chemotherapy and toripalimab for larynx preservation in resectable locally advanced laryngeal/hypopharyngeal carcinoma: Preliminary results of INSIGHT study. *J Clin Oncol* 41, 2023 (suppl 16; abstr 6068)
5. Wu D et al. A pilot phase II trial of neoadjuvant camrelizumab plus nab-paclitaxel and cisplatin (NeoCPC) for locoregionally advanced, resectable squamous cell carcinoma of the head and neck. *J Clin Oncol* 41, 2023 (suppl 16; abstr 6069)
6. Chen Y et al. Neoadjuvant chemoimmunotherapy for the treatment of locally advanced laryngeal and hypopharyngeal squamous cell carcinoma: A single-arm phase 2 clinical trial. *J Clin Oncol* 41, 2023 (suppl 16; abstr 6077)
7. Gui L et al. Tislelizumab plus chemotherapy as induction treatment followed by chemoradiotherapy or surgery in locally advanced hypopharyngeal squamous cell carcinoma: A single-arm, phase II trial. *J Clin Oncol* 41, 2023 (suppl 16; abstr 6087)
8. Yan J et al. Neoadjuvant tislelizumab combined with APF for patients with locally advanced head and neck squamous cell carcinoma: A prospective single-arm clinical trial. *J Clin Oncol* 41, 2023 (suppl 16; abstr 6080)
9. Ferrarotto R et al. Immuno-chemotherapy as single treatment modality for larynx preservation (ICoLP): Co-primary endpoints and safety results. *J Clin Oncol* 41, 2023 (suppl 16; abstr 6008)
10. Ferris RL et al. Neoadjuvant nivolumab alone or in combination with relatlimab or ipilimumab in resectable head and neck squamous cell carcinoma (HNSCC). *J Clin Oncol* 41, 2023 (suppl 16; abstr 6018)
11. Ottensmeier CHH et al. Safety and immunogenicity of TG4050: A personalized cancer vaccine in head and neck carcinoma. *J Clin Oncol* 41, 2023 (suppl 16; abstr 6082)
12. Kim HR et al. Neoadjuvant pembrolizumab, GX-188E, and GX-I7 in patients with human papillomavirus-16- and/or 18-positive head and neck squamous cell carcinoma: Single-arm, phase 2 trial with single cell transcriptomic analysis and artificial intelligence-powered spatial analysis. *J Clin Oncol* 41, 2023 (suppl 16; abstr 6075)
13. De Los Santos JF et al. Combined pulsed radiotherapy (QUAD shot regimen) with immune checkpoint inhibition (ICI) to enhance immune response for LAHNSCC in patients considered ineligible for curative intent therapy. *J Clin Oncol* 41, 2023 (suppl 16; abstr 6083)
14. Posner MR et al. The Quarterback trials: A phase 2 series of sequential studies of induction chemotherapy followed by reduced dose chemoradiation for human papillomavirus positive oropharynx cancer. *J Clin Oncol* 41, 2023 (suppl 16; abstr 6020)
15. Skinner HD et al. Phase II trial of adjuvant de-escalated radiation + adjuvant nivolumab for intermediate-high risk P16+ oropharynx cancer. *J Clin Oncol* 41, 2023 (suppl 16; abstr 6014)
16. Ferris RL et al. Outcomes by time to adjuvant therapy in E3311, a phase II trial of transoral surgery (TOS) followed by pathology-based adjuvant treatment in HPV-associated (HPV+) oropharynx cancer (OPC): A trial of the ECOG-ACRIN Cancer Research Group. *J Clin Oncol* 41, 2023 (suppl 16; abstr 6036)
17. Garcia ES et al. Multimodal detection in plasma of molecular residual disease (MRD) in locally advanced head and neck squamous cell carcinoma (LA-HNSCC). *J Clin Oncol* 41, 2023 (suppl 16; abstr 6065)

18. Fayette J et al. Results of the multicenter phase II FRAIL-IMMUNE trial evaluating the efficacy and safety of durvalumab combined with weekly paclitaxel carboplatin in first-line in patients (pts) with recurrent/metastatic squamous cell carcinoma of the head and neck (R/M SCCHN) not eligible for cisplatin-based therapies. J Clin Oncol 41, 2023 (suppl 16; abstr 6003)
19. Sun L et al. Platinum/taxane/pembrolizumab vs platinum/5FU/pembrolizumab in patients with recurrent/metastatic (r/m) head and neck squamous cell carcinoma (HNSCC). J Clin Oncol 41, 2023 (suppl 16; abstr 6039)
20. Cohen J et al. Nanoparticle albumin-bound (nab) paclitaxel in combination with nivolumab as treatment of recurrent or metastatic head and neck squamous-cell carcinoma (RM-HNSCC) that progressed on a PD-1 inhibitor: A single-arm, phase 2 trial. J Clin Oncol 41, 2023 (suppl 16; abstr 6023)
21. Hanna GJ et al. Dose expansion results of the bifunctional EGFR/TGFβ inhibitor BCA101 with pembrolizumab in patients with recurrent, metastatic head and neck squamous cell carcinoma. J Clin Oncol 41, 2023 (suppl 16; abstr 6005)
22. Price KAR et al. Safety and efficacy of immune checkpoint inhibitor (ICI) naïve cohort from study of PDS0101 and pembrolizumab in HPV16-positive head and neck squamous cell carcinoma (HNSCC). J Clin Oncol 41, 2023 (suppl 16; abstr 6012)
23. Kong AH et al. Phase 2 study of ISA101b (peltopepimut-S) and cemiplimab in patients with advanced HPV16+ oropharyngeal cancer who failed anti-PD1 therapy. J Clin Oncol 41, 2023 (suppl 16; abstr 6028)
24. Chung CH et al. A phase 1 dose-escalation and expansion study of CUE-101, a novel HPV16 E7-pHLA-IL2-Fc fusion protein, given as monotherapy and in combination with pembrolizumab in patients with recurrent/metastatic HPV16+ head and neck cancer. J Clin Oncol 41, 2023 (suppl 16; abstr 6013)
25. de Spéville BD et al. Final results from TACTI-002 Part C: A phase II study of eftilagimod alpha (soluble LAG-3 protein) and pembrolizumab in patients with metastatic 2nd line head and neck squamous cell carcinoma unselected for PD-L1. J Clin Oncol 41, 2023 (suppl 16; abstr 6029)
26. Cohen J et al. Olaparib, a poly (ADP-ribose) polymerase (PARP) inhibitor, in combination with pembrolizumab and carboplatin as first-line treatment of recurrent or metastatic head and neck squamous-cell carcinoma (RM-HNSCC): A single-arm, phase 2 trial. J Clin Oncol 41, 2023 (suppl 16; abstr 6016)
27. Swiecicki P et al. Enfortumab vedotin in the previously treated advanced head and neck cancer (HNC) cohort of EV-202. J Clin Oncol 41, 2023 (suppl 16; abstr 6017)
28. Xue L et al. Results from two phase II studies of SI-B001, an EGFR×HER3 bispecific antibody, with/without chemotherapy in patients (pts) with recurrent and metastatic head and neck squamous cell carcinoma (HNSCC). J Clin Oncol 41, 2023 (suppl 16; abstr 6037)
29. Desilets A et al. A phase 1 study of concurrent cabozantinib and cetuximab in recurrent or metastatic head and neck squamous cell cancer. J Clin Oncol 41, 2023 (suppl 16; abstr 6025)
30. Galot R et al. Afatinib in patients with recurrent/metastatic (RM) squamous cell carcinoma of the head and neck (SCCHN) harboring alterations in the HER pathway: Results of the B1 cohort of the EORTC-HNCG-1559 trial (UPSTREAM). J Clin Oncol 41, 2023 (suppl 16; abstr 6034)

31. Puram S et al. Tazemetostat, a selective EZH2 inhibitor, with pembrolizumab as treatment of anti-PD-1 resistant head and neck squamous-cell carcinoma (HNSCC): A phase 1-2 trial. *J Clin Oncol* 41, 2023 (suppl 16; abstr 6022)
32. Chakravarthy K et al. Evaluation of ICI sensitivity for pembrolizumab in combination with anti-platelet therapy for patients with recurrent or metastatic squamous cell carcinoma of the head and neck (HNSCC). *J Clin Oncol* 41, 2023 (suppl 16; abstr 6041)
33. Oppelt PJ et al. Correlation of CDKN2A genomic alterations with tumor response to palbociclib given before chemoradiation therapy (CRT) to patients with human papillomavirus (HPV)-negative, locally advanced head and neck squamous-cell carcinoma (LA-HNSCC): A single-arm, phase 2 trial. *J Clin Oncol* 41, 2023 (suppl 16; abstr 6015)
34. Koyama T et al. A phase II trial of paclitaxel plus biweekly cetuximab for patients with recurrent or metastatic head and neck cancer previously treated with both platinum-based chemotherapy and anti-PD-1 antibody. *J Clin Oncol* 41, 2023 (suppl 16; abstr 6032)
35. Thyparambil SP et al. Personalized therapy for head and neck squamous carcinoma (HNSCC) utilizing tissue proteomics profiling. *J Clin Oncol* 41, 2023 (suppl 16; abstr 6045)
36. Liu J et al. A proteomic signature associated with prognosis in HPV-related locally advanced oropharyngeal squamous cell carcinoma (LA-OPSCC). *J Clin Oncol* 41, 2023 (suppl 16; abstr 6055)
37. Jiang X et al. Single-cell RNA and T cell receptor (TCR) sequencing in patients with HPV-positive head and neck squamous cell carcinoma (HNSCC) after induction CTLA4 and PD-1 immune checkpoint blockade (ICB). *J Clin Oncol* 41, 2023 (suppl 16; abstr 6056)
38. Garb BF et al. Introduction of E-Score: A gene expression score to characterize immunogenic versus oncogenic HPV expression in HNSCC. *J Clin Oncol* 41, 2023 (suppl 16; abstr 6057)
39. Wotman M et al. Association of HPV genotype and phylogenetic clade with oropharyngeal cancer outcomes. *J Clin Oncol* 41, 2023 (suppl 16; abstr 6058)
40. Choe JH et al. Spatial genomics to reveal an immunosuppressive tumor microenvironment after chemoradiation in head and neck cancer patients. *J Clin Oncol* 41, 2023 (suppl 16; abstr 6059)
41. Feng M et al. Low-dose fractionated radiotherapy combined with neoadjuvant chemotherapy for T3-4 nasopharyngeal carcinoma patients: Preliminary results of a phase II randomized controlled trial. *J Clin Oncol* 41, 2023 (suppl 16; abstr 6049)
42. Kong FF et al. Radiotherapy alone versus concurrent or adjuvant chemoradiotherapy for nasopharyngeal carcinoma patients with negative Epstein-Barr virus DNA post-induction chemotherapy. *J Clin Oncol* 41, 2023 (suppl 16; abstr 6064)
43. Chen M et al. Induction chemotherapy plus radiotherapy alone versus cisplatin-based concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: An open-label, non-inferiority, randomized phase 3 trial. *J Clin Oncol* 41, 2023 (suppl 16; abstr 6001)
44. Tang L et al. Concurrent chemoradiotherapy followed by adjuvant cisplatin-gemcitabine versus cisplatin-5-fluorouracil chemotherapy for N2-3 nasopharyngeal carcinoma: A multicentre, open-label, randomised, controlled, phase 3 trial. *J Clin Oncol* 41, 2023 (suppl 16; abstr 6000)
45. Fangzheng C et al. Induction chemotherapy with nedaplatin, docetaxel and 5-fluorouracil followed by concurrent nedaplatin and radiotherapy in locoregionally advanced nasopharyngeal carcinoma: A single arm, open label, phase II clinical trial. *J Clin Oncol* 41, 2023 (suppl 16; abstr 6067)

46. Lv X et al. Nab-paclitaxel plus cisplatin versus docetaxel plus cisplatin and 5-FU induction chemotherapy followed by concurrent chemoradiotherapy in locally advanced nasopharyngeal carcinoma: A multicenter parallel controlled phase III trial. *J Clin Oncol* 41, 2023 (suppl 16; abstr 6071)
47. Hui EP et al. NEOSPACE trial: Neoadjuvant pembrolizumab-gemcitabine-cisplatin followed by concurrent pembrolizumab-chemoradiation and maintenance pembrolizumab for stage IVA nasopharyngeal cancer (NPC). *J Clin Oncol* 41, 2023 (suppl 16; abstr 6010)
48. Ma J et al. PD-1 blockade with sintilimab plus induction chemotherapy and concurrent chemoradiotherapy (IC-CCRT) versus IC-CCRT in locoregionally-advanced nasopharyngeal carcinoma (LANPC): A multicenter, phase 3, randomized controlled trial (CONTINUUM). *J Clin Oncol* 41, 2023 (suppl 17; abstr LBA6002)
49. Mai H et al. Final overall survival analysis of JUPITER-02: A phase 3 study of toripalimab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (NPC). *J Clin Oncol* 41, 2023 (suppl 16; abstr 6009)
50. Mai H et al. A phase Ib/II study of GFH018 in combination with toripalimab in recurrent/metastatic nasopharyngeal carcinoma (R/M NPC). *J Clin Oncol* 41, 2023 (suppl 16; abstr 6026)
51. Lu N et al. Efficacy and safety of sintilimab plus bevacizumab in metastatic nasopharyngeal carcinoma after failure of platinum-based chemotherapy: An open-label phase II study. *J Clin Oncol* 41, 2023 (suppl 16; abstr 6031)
52. Jia Q et al. TCR-T cells armored with immune checkpoint blockade in EBV-positive nasopharyngeal carcinoma: The first-in-human phase 1/2 trial. *J Clin Oncol* 41, 2023 (suppl 16; abstr 6047)
53. Weijers JAM et al. Retrospective analysis of genetically matched therapies in salivary gland cancer entities using a real-world database in a tertiary salivary gland cancer expertise center. *J Clin Oncol* 41, 2023 (suppl 16; abstr 6098)
54. Kang H et al. Updated results from a phase 2 study of the oral vascular endothelial growth factor receptor 2 (VEGFR2) inhibitor rivoceranib for recurrent or metastatic (R/M) adenoid cystic carcinoma (ACC). *J Clin Oncol* 41, 2023 (suppl 16; abstr 6040)
55. Van Herpen CML et al. ¹⁷⁷Lu-PSMA radioligand therapy for recurrent/metastatic (R/M) salivary gland cancer (SGC) patients: A phase II pilot study. *J Clin Oncol* 41, 2023 (suppl 16; abstr 6099)
56. Okano S et al. Darolutamide for patients with androgen receptor positive salivary gland cancers (DISCOVARY): The results of phase 2 study of darolutamide monotherapy. *J Clin Oncol* 41, 2023 (suppl 16; abstr 6093)
57. Nagatani Y et al. A phase II trial of nivolumab for patients with platinum-refractory recurrent or metastatic salivary gland cancer. *J Clin Oncol* 41, 2023 (suppl 16; abstr 6092)
58. Hoff CO et al. Predictive biomarkers of benefit to axitinib plus avelumab in patients with recurrent/metastatic adenoid cystic carcinoma (R/M ACC). *J Clin Oncol* 41, 2023 (suppl 16; abstr 6096)
59. Rodriguez CP et al. Dual PD1 and CTLA4 immune checkpoint blockade and hypofractionated radiation in patients with salivary gland cancers. *J Clin Oncol* 41, 2023 (suppl 16; abstr 6011)
60. Contrera KJ et al. Phase II prospective trial of induction chemotherapy for advanced sinonasal squamous cell or poorly differentiated carcinoma. *J Clin Oncol* 41, 2023 (suppl 16; abstr 6090)

Neurologische Toxizität neuer Tumorthapien (S. 16–19)

H. Strik

Literatur:

1. Robert C. A decade of immune-checkpoint inhibitors in cancer therapy. *Nat Commun* 2020; 11(1): 3801
2. Carlino MS, Larkin J, Long GV. Immune checkpoint inhibitors in melanoma. *Lancet* 2021; 398: 1002–14
3. Jia XH et al. The biomarkers related to immune related adverse events caused by immune checkpoint inhibitors. *J Exp Clin Cancer Res* 2020; 39(1): 284
4. Ruggiero R et al. Neurological Manifestations Related to Immune Checkpoint Inhibitors: Reverse Translational Research by Using the European Real-World Safety Data. *Front Oncol* 2022; 12: 824511
5. Roth P et al. Neurological complications of cancer immunotherapy. *Cancer Treat Rev* 2021; 97: 102189
6. Knauss S et al. Neurologische Nebenwirkungen von Checkpoint-Inhibitoren [Neurological side effects of checkpoint inhibitors]. *Nervenarzt* 2019; 90(2): 138–47
7. Strik H et al. Immune checkpoint inhibitor-associated CNS autoimmune disorder (ICICAD) following nivolumab treatment: A new entity of drug-induced autoimmune encephalitis? *Eur J Cancer* 2017; 87: 205–8
8. Salvaris R, Ong J, Gregory GP. Bispecific Antibodies: A Review of Development, Clinical Efficacy and Toxicity in B-Cell Lymphomas. *J Pers Med* 2021; 11(5): 355
9. Stein AS et al. Neurologic adverse events in patients with relapsed/refractory acute lymphoblastic leukemia treated with blinatumomab: management and mitigating factors. *Ann Hematol* 2019; 98(1): 159–67
10. Jain T, Litzow MR. Management of toxicities associated with novel immunotherapy agents in acute lymphoblastic leukemia. *Ther Adv Hematol* 2020; 11: 2040620719899897
11. Holzinger A, Abken H. Chimäre Antigenrezeptoren (CAR) – universelle Werkzeuge in der zellulären Immuntherapie [Chimeric antigen receptors (CARs): universal tools in adoptive cell therapy]. *Internist (Berl)* 2021; 62(6): 583–88

12. Pennisi M et al. Comparing CAR T-cell toxicity grading systems: application of the ASTCT grading system and implications for management. *Blood Adv* 2020; 4(4): 676–86
13. Santomasso B et al. The Other Side of CAR T-Cell Therapy: Cytokine Release Syndrome, Neurologic Toxicity, and Financial Burden. *Am Soc Clin Oncol Educ Book* 2019; 39: 433–44

Aktuelles zum gesetzlichen Früherkennungsprogramm des Zervixkarzinoms in Deutschland (S. 24–31)

A. Behrens, M.W. Beckmann, F.A. Stübs

Literatur:

1. Gebärmutterhalskrebs (Zervixkarzinom) Zentrum für Krebsregisterdaten, Robert Koch Institut.
(https://www.krebsdaten.de/Krebs/DE/Content/Krebsarten/Gebaermutterhalskrebs/gebaermutterhalskrebs_node.html;jsessionid=7B14DC22C6CDDDBB18F5D07AA0AE1452.internet072). Zugegriffen am 22.07.2022
2. Schiffman M et al. Human papillomavirus and cervical cancer. *Lancet* 2007; 370(9590): 890–907
3. Ständige Impfkommision: Empfehlungen der Ständigen Impfkommision (STIKO) beim Robert Koch-Institut 2022. *Epid Bull* 2022. 3-66
4. Stübs FA et al. HPV-Diagnostik und Therapie in der Prävention. *Frauenheilkunde* up2date 2021; 15 (6): 537–49
5. Stübs FA et al. Krebsfrüherkennung des weiblichen Genitales. *Frauenheilkunde* up2date 2018; 12 (6): 519–29
6. Schulmeyer CE et al. Gynäkologische Krebsfrüherkennung des Zervixkarzinoms im Wandel der Zeit. *Gyn Praktische Gynäkologie* 2017; 5: 386
7. Stuebs FA et al. Human papilloma virus genotype distribution in women with premalignant or malignant lesions of the uterine cervix. *Arch Gynecol Obstet* 2021; 304(3): 751–8
8. Bosch FX et al. Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International biological study on cervical cancer (IBSCC) Study Group. *J Natl Cancer Inst* 1995; 87(11): 796–802
9. Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF). Prävention des Zervixkarzinoms, Langversion 1.1, 2020. AWMF Registernummer: 015/027OL.
(https://www.awmf.org/uploads/tx_szleitlinien/082-002l_S3_Impfpraevention-HPV-assoziiierter-Neoplasien_2020-07_01.pdf). Zugegriffen am 31.07.2022

10. Richtlinie des Gemeinsamen Bundesausschusses für organisierte Krebsfrüherkennungsprogramme oKFE-Richtlinie/oKFE-RL. (<https://www.g-ba.de/downloads/62-492-2605/oKFE-RL-2021-07-01-iK-2022-01-01.pdf>). Zugriffen am 03.08.2022
11. Hillemanns P et al. Statement of the AGO and AG-CPC on the Aftercare/Follow-up for Surgical Procedures of the Lower Genital Tract after the Introduction of a New Cancer Screening Guideline. *Geburtshilfe und Frauenheilkunde* 2020; 80: 809–12
12. Stuebs FA et al. Cytology and High-Risk Human Papillomavirus Test for Cervical Cancer Screening Assessment. *Diagnostics (Basel)* 2022; 12(7)
13. Karimi-Zarchi M et al. A Comparison of 3 Ways of Conventional Pap Smear, Liquid-Based Cytology and Colposcopy vs Cervical Biopsy for Early Diagnosis of Premalignant Lesions or Cervical Cancer in Women with Abnormal Conventional Pap Test. *Int J Biomed Sci* 2013; 9(4): 205–10
14. Muller K et al. Accuracy of Colposcopically Guided Diagnostic Methods for the Detection of Cervical Intraepithelial Neoplasia. *Geburtshilfe Frauenheilkd* 2016; 76(2): 182–7
15. Marquardt K et al. An der Schwelle zum organisierten Zervixkarzinomscreening. Befunde der Münchner Nomenklatur III und zytologisch-histologische Korrelation. *Der Gynäkologe* 2019; 52: 622–7
16. Marquardt K et al. Risikobewertung von Zytologiebefunden im Zervixkarzinom-Screening. *Gynäkologe* 2019; 52: 937–44
17. Beckmann MW et al. Establishment of the Certification System "Gynaecological Dysplasia" in Germany. *Geburtshilfe Frauenheilkd* 2014; 74(9): 860–7
18. Arbeitsgemeinschaft Zervixpathologie und Kolposkopie e.V. Dysplasieportal. (<https://www.dysplasieportal.de/>). Zugriffen am 14.08.2022
19. Deutsche Krebsgesellschaft. OncoMap. (<https://www.oncomap.de/cnetworks/cnoncos?selectedCounty=Deutschland&selectedCerttype=DKG>). Zugriffen am 14.08.2022
20. Lei J et al. HPV Vaccination and the Risk of Invasive Cervical Cancer. *N Engl J Med* 2020; 383(14): 1340–8
21. Garland SM. The Australian experience with the human papillomavirus vaccine. *Clin Ther* 2014; 36(1): 17–23
22. Munoz N et al. Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24–45 years: a randomised, double-blind trial. *Lancet* 2009; 373(9679): 1949–57
23. Olsson SE et al. Evaluation of quadrivalent HPV 6/11/16/18 vaccine efficacy against cervical and anogenital disease in subjects with serological evidence of prior vaccine type HPV infection. *Hum Vaccin* 2009; 5(10): 696–704
24. Schwarz TF et al. Immunogenicity and tolerability of an HPV-16/18 AS04-adjuvanted prophylactic cervical cancer vaccine in women aged 15–55 years. *Vaccine* 2009; 27(4): 581–7
25. Castellsague X et al. HPV vaccination against cervical cancer in women above 25 years of age: key considerations and current perspectives. *Gynecol Oncol* 2009; 115(3 Suppl): 15–23

26. Harper DM et al. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. *Lancet* 2006; 367(9518): 1247–55
27. Kang WD et al. Is vaccination with quadrivalent HPV vaccine after loop electrosurgical excision procedure effective in preventing recurrence in patients with high-grade cervical intraepithelial neoplasia (CIN2-3)? *Gynecol Oncol* 2013; 130(2): 264–8
28. Lichter K et al. Adjuvant Human Papillomavirus Vaccine to Reduce Recurrent Cervical Dysplasia in Unvaccinated Women: A Systematic Review and Meta-analysis. *Obstet Gynecol* 2020; 135(5): 1070–83
29. Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF). Impfprävention HPV-assoziiierter Neoplasien, Langversion 1.1, 2020. AWMF Registernummer: 082-002.
(https://www.awmf.org/uploads/tx_szleitlinien/082-002l_S3_Impfpraevention-HPV-assoziiierter-Neoplasien_2020-07_01.pdf). Zugriffen am 02.08.2022
30. Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF). Diagnostik, Therapie und Nachsorge der Patientin mit Zervixkarzinom. Langversion 2.2, 2022. AWMF-Registernummer: 032/033OL.
(https://www.leitlinienprogramm-onkologie.de/fileadmin/user_upload/Downloads/Leitlinien/Zervixkarzinom/Version_2/LL_Zervixkarzinom_Langversion_2.2.pdf). Zugriffen am 02.08.2022

Metastasiertes Mammakarzinom in der Harnblase (S. 32–33)

A. Zemam, M. Nikolov, K.J. Schmitz, A. Holstein, B. Planz

Literatur:

1. Karaosmanoglu AD et al. Secondary Tumors of the Urinary System: An Imaging Conundrum 2018; 19(4): 742–51
2. Junejo NN et al. Unusual pattern of breast carcinoma metastasis to the urinary bladder: case report and review of literature. *Saudi Surgical Journal* 2018; 6: 66–8
3. Karjol U et al. Bladder Metastasis from Breast Cancer: A Systematic Review *Cureus* 2020; 12(3): e7408
4. Feldman PA et al. Metastatic breast cancer to the bladder: a diagnostic challenge and review of the literature. *Urology* 2002; 59(1): 138
5. Gitau SN et al. Urinary bladder metastasis from breast cancer: a rare cause of hematuria, *BJR Case Rep* 2020; 6: 120190048
6. Ghaida RA et al. Bladder metastasis from primary breast cancer: a case report and literature review, *Cent European J Urol* 2013; 66(2): 177–84
7. Sanguedolce F et al. Bladder Metastases from Breast Cancer: Managing the Unexpected. A Systematic Review *Urol Int* 2018; 101: 125–31